Michael Kozal, MD

• Albert C Shaw
• Amy Justice
• Ann Fisher
• Asim Tarabar
• Christopher Ruser
• Cynthia Brandt
• Daniel Federman
• David Fiellin
• David Peaper
• Erol Fikrig
• Frederick Altice
• Gary Stack
• Gerald Friedland
• Heidi J Zapata
• Jeanette Tetrault
• Jonathan Rothberg
• Joseph Lucien Goulet
• Lydia Aoun-Barakat
• Lynn E Fiellin
• Marc Rosen
• Marie-Louise Landry
• Max Lataillade
• Nikhil Seval
• Richard Lifton
• Richard Sutton
• Samit Joshi
• Sandra Ann Springer
• Serena Spudich
• Shaili Gupta
• Sheela Shenoi
• Sheldon Campbell
• Tassos C. Kyriakides

Acquired Immunodeficiency Syndrome; Clinical Trials as Topic; Drug Resistance; Hepatitis C; HIV; Veterans; Infectious Disease Medicine

• A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients.Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. The Journal Of Infectious Diseases 1993, 167: 526-32 PubMed ID: 7680058, DOI: 10.1093/infdis/167.3.526.
• Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy.Holodniy M, Katzenstein D, Winters M, Montoya J, Shafer R, Kozal M, Ragni M, Merigan TC. Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. Journal Of Acquired Immune Deficiency Syndromes (1999) 1993, 6: 366-9 PubMed ID: 8095981.
• Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates.Shafer RW, Kozal MJ, Katzenstein DA, Lipil WH, Johnstone IF, Merigan TC. Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates. Journal Of Virological Methods 1993, 41: 297-310 PubMed ID: 8097199, DOI: 10.1016/0166-0934(93)90019-n.
• HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients.Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Aguiniga E, Halpern J, Merigan TC. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients. Journal Of Acquired Immune Deficiency Syndromes (1999) 1994, 7: 832-8 PubMed ID: 7517448.
• Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, Merigan TC. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Annals Of Internal Medicine 1994, 121: 263-8 PubMed ID: 7518658, DOI: 10.7326/0003-4819-121-4-199408150-00005.
• Prevalence of HIV-1 syncytium-inducing phenotype.Kozal MJ, Ramachandran RV, Shafer RW. Prevalence of HIV-1 syncytium-inducing phenotype. Annals Of Internal Medicine 1994, 120: 811 PubMed ID: 7908508, DOI: 10.7326/0003-4819-120-9-199405010-00019.
• Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA.Kroodsma KL, Kozal MJ, Hamed KA, Winters MA, Merigan TC. Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA. The Journal Of Infectious Diseases 1994, 170: 1292-5 PubMed ID: 7963730, DOI: 10.1093/infdis/170.5.1292.
• Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.Shafer RW, Kozal MJ, Winters MA, Iversen AK, Katzenstein DA, Ragni MV, Meyer WA, Gupta P, Rasheed S, Coombs R. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. The Journal Of Infectious Diseases 1994, 169: 722-9 PubMed ID: 8133086, DOI: 10.1093/infdis/169.4.722.
• Using oligonucleotide probe arrays to access genetic diversity.Lipshutz RJ, Morris D, Chee M, Hubbell E, Kozal MJ, Shah N, Shen N, Yang R, Fodor SP. Using oligonucleotide probe arrays to access genetic diversity. BioTechniques 1995, 19: 442-7 PubMed ID: 7495558.
• The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, Merigan TC. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Annals Of Internal Medicine 1996, 124: 1039-50 PubMed ID: 8633817, DOI: 10.7326/0003-4819-124-12-199606150-00003.
• Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays.Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan TC, Richman DD, Morris D, Hubbell E, Chee M, Gingeras TR. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nature Medicine 1996, 2: 753-9 PubMed ID: 8673920, DOI: 10.1038/nm0796-753.
• Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care.Kozal MJ, Amico KR, Chiarella J, Schreibman T, Cornman D, Fisher W, Fisher J, Friedland G. Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care. AIDS (London, England) 2004, 18: 2185-9 PubMed ID: 15577652, DOI: 10.1097/00002030-200411050-00011.
• Cross-resistance patterns among HIV protease inhibitors.Kozal M. Cross-resistance patterns among HIV protease inhibitors. AIDS Patient Care And STDs 2004, 18: 199-208 PubMed ID: 15142350, DOI: 10.1089/108729104323038874.
• Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons.MacArthur RD, Chen L, Peng G, Novak RM, van den Berg-Wolf M, Kozal M, Besch L, Yurik T, Schmetter B, Henley C, Dehlinger M. Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons. HIV Clinical Trials 2004, 5: 361-70 PubMed ID: 15682349, DOI: 10.1310/WEQG-QTHL-DL3X-FTXC.
• HIV drug resistance and HIV transmission risk behaviors among active injection drug users.Kozal MJ, Amico KR, Chiarella J, Cornman D, Fisher W, Fisher J, Friedland G. HIV drug resistance and HIV transmission risk behaviors among active injection drug users. Journal Of Acquired Immune Deficiency Syndromes (1999) 2005, 40: 106-9 PubMed ID: 16123691, DOI: 10.1097/01.qai.0000159666.95455.d2.
• Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy.Novak RM, Chen L, MacArthur RD, Baxter JD, Huppler Hullsiek K, Peng G, Xiang Y, Henely C, Schmetter B, Uy J, van den Berg-Wolf M, Kozal M. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America 2005, 40: 468-74 PubMed ID: 15668873, DOI: 10.1086/427212.
• A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Hullsiek KH, Kozal MJ, van den Berg-Wolf M, Henely C, Schmetter B, Dehlinger M. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 2006, 368: 2125-35 PubMed ID: 17174704, DOI: 10.1016/S0140-6736(06)69861-9.
• The hunt for HIV-1 integrase inhibitors.Lataillade M, Kozal MJ. The hunt for HIV-1 integrase inhibitors. AIDS Patient Care And STDs 2006, 20: 489-501 PubMed ID: 16839248, DOI: 10.1089/apc.2006.20.489.
• Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.Kozal MJ, Hullsiek KH, Leduc R, Novak RM, MacArthur RD, Lawrence J, Baxter JD. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients. Antiviral Therapy 2006, 11: 457-63 PubMed ID: 16856619.
• A population-based and longitudinal study of sexual behavior and multidrug-resistant HIV among patients in clinical care.Kozal MJ, Amico KR, Chiarella J, Cornman D, Fisher W, Fisher J, Friedland G. A population-based and longitudinal study of sexual behavior and multidrug-resistant HIV among patients in clinical care. MedGenMed : Medscape General Medicine 2006, 8: 72 PubMed ID: 16926811, PMCID: PMC1785162, DOI: 10.1186/1758-2652-8-2-72.
• The Incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naïve participants started on three different antiretroviral therapy strategies.Kozal MJ, Hullsiek KH, Macarthur RD, Berg-Wolf Mv, Peng G, Xiang Y, Baxter JD, Uy J, Telzak EE, Novak RM. The Incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naïve participants started on three different antiretroviral therapy strategies. HIV Clinical Trials 2007, 8: 357-70 PubMed ID: 18042501, DOI: 10.1310/hct0806-357.
• Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: results from a randomized controlled trial.Maru DS, Kozal MJ, Bruce RD, Springer SA, Altice FL. Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: results from a randomized controlled trial. Journal Of Acquired Immune Deficiency Syndromes (1999) 2007, 46: 555-63 PubMed ID: 18193497, PMCID: PMC2684061, DOI: 10.1097/qai.0b013e318158c0bd.
• Evolution of genotypic resistance algorithms and their impact on the interpretation of clinical trials: an OPTIMA trial substudy.Desai S, Kyriakides T, Holodniy M, Al-Salman J, Griffith B, Kozal M. Evolution of genotypic resistance algorithms and their impact on the interpretation of clinical trials: an OPTIMA trial substudy. HIV Clinical Trials 2007, 8: 293-302 PubMed ID: 17956830, DOI: 10.1310/hct0805-293.
• Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies.Braithwaite RS, Kozal MJ, Chang CC, Roberts MS, Fultz SL, Goetz MB, Gibert C, Rodriguez-Barradas M, Mole L, Justice AC. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS (London, England) 2007, 21: 1579-89 PubMed ID: 17630553, PMCID: PMC3460378, DOI: 10.1097/QAD.0b013e3281532b31.
• Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antiviral Therapy 2007, 12: 563-70 PubMed ID: 17668566.
• Hepatitis C protease and polymerase inhibitors in development.Liu-Young G, Kozal MJ. Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care And STDs 2008, 22: 449-57 PubMed ID: 18479202, PMCID: PMC2928549, DOI: 10.1089/apc.2007.0199.
• Attitudes toward needle-sharing and HIV transmission risk behavior among HIV+ injection drug users in clinical care.Norton WE, Amico KR, Fisher WA, Copenhaver MM, Kozal MJ, Cornman DH, Friedland G, Fisher JD. Attitudes toward needle-sharing and HIV transmission risk behavior among HIV+ injection drug users in clinical care. AIDS Care 2008, 20: 462-9 PubMed ID: 18449824, DOI: 10.1080/09540120701867081.
• Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons.van den Berg-Wolf M, Hullsiek KH, Peng G, Kozal MJ, Novak RM, Chen L, Crane LR, Macarthur RD. Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. HIV Clinical Trials 2008, 9: 324-36 PubMed ID: 18977721, DOI: 10.1310/hct0905-324.
• Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use.Le T, Chiarella J, Simen BB, Hanczaruk B, Egholm M, Landry ML, Dieckhaus K, Rosen MI, Kozal MJ. Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PloS One 2009, 4: e6079 PubMed ID: 19562031, PMCID: PMC2698118, DOI: 10.1371/journal.pone.0006079.
• Development of an electronic medical record-based clinical decision support tool to improve HIV symptom management.Nader CM, Tsevat J, Justice AC, Mrus JM, Levin F, Kozal MJ, Mattocks K, Farber S, Rogers M, Erdos J, Brandt C, Kudel I, Braithwaite R. Development of an electronic medical record-based clinical decision support tool to improve HIV symptom management. AIDS Patient Care And STDs 2009, 23: 521-9 PubMed ID: 19538046, PMCID: PMC3048777, DOI: 10.1089/apc.2008.0209.
• Drug-resistant human immunodefiency virus.Kozal MJ. Drug-resistant human immunodefiency virus. Clinical Microbiology And Infection : The Official Publication Of The European Society Of Clinical Microbiology And Infectious Diseases 2009, 15 Suppl 1: 69-73 PubMed ID: 19220361, DOI: 10.1111/j.1469-0691.2008.02687.x.
• Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants.Gupta S, Lataillade M, Farber S, Kozal MJ. Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants. Journal Of The International Association Of Physicians In AIDS Care (Chicago, Ill. : 2002) 2009, 8: 87-92 PubMed ID: 19270153, DOI: 10.1177/1545109709332471.
• Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, Huang C, Lubeski C, Turenchalk GS, Braverman MS, Desany B, Rothberg JM, Egholm M, Kozal MJ. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. The Journal Of Infectious Diseases 2009, 199: 693-701 PubMed ID: 19210162, DOI: 10.1086/596736.
• Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study.Lataillade M, Chiarella J, Yang R, Schnittman S, Wirtz V, Uy J, Seekins D, Krystal M, Mancini M, McGrath D, Simen B, Egholm M, Kozal M. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study. PloS One 2010, 5: e10952 PubMed ID: 20532178, PMCID: PMC2880604, DOI: 10.1371/journal.pone.0010952.
• Epidemiology, seasonality, and predictors of outcome of AIDS-associated Penicillium marneffei infection in Ho Chi Minh City, Viet Nam.Le T, Wolbers M, Chi NH, Quang VM, Chinh NT, Lan NP, Lam PS, Kozal MJ, Shikuma CM, Day JN, Farrar J. Epidemiology, seasonality, and predictors of outcome of AIDS-associated Penicillium marneffei infection in Ho Chi Minh City, Viet Nam. Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America 2011, 52: 945-52 PubMed ID: 21427403, PMCID: PMC3106230, DOI: 10.1093/cid/cir028.
• Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.Kozal MJ, Chiarella J, St John EP, Moreno EA, Simen BB, Arnold TE, Lataillade M. Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels. Antiviral Therapy 2011, 16: 925-9 PubMed ID: 21900725, DOI: 10.3851/IMP1851.
• Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM, Thiebaut R, Ostergaard L, Masquelier B, Johnson JA, Miller MD, Kuritzkes DR. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011, 305: 1327-35 PubMed ID: 21467286, PMCID: PMC3325645, DOI: 10.1001/jama.2011.375.
• Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.Lataillade M, Chiarella J, Yang R, DeGrosky M, Uy J, Seekins D, Simen B, St John E, Moreno E, Kozal M. Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing. PloS One 2012, 7: e30118 PubMed ID: 22355307, PMCID: PMC3280244, DOI: 10.1371/journal.pone.0030118.
• A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.Kozal MJ, Lupo S, DeJesus E, Molina JM, McDonald C, Raffi F, Benetucci J, Mancini M, Yang R, Wirtz V, Percival L, Zhang J, Zhu L, Arikan D, Farajallah A, Nguyen BY, Leavitt R, McGrath D, Lataillade M, The Spartan Study Team. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results. HIV Clinical Trials 2012, 13: 119-30 PubMed ID: 22592092, DOI: 10.1310/hct1303-119.
• Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure.Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Kozal MJ, Hullsiek KH, Miller MD, Bangsberg DR, Kuritzkes DR. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS (London, England) 2012, 26: 185-92 PubMed ID: 22179227, PMCID: PMC3437231, DOI: 10.1097/QAD.0b013e32834e9d7d.
• Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations.Winters MA, Lloyd RM, Shafer RW, Kozal MJ, Miller MD, Holodniy M. Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations. PloS One 2012, 7: e40514 PubMed ID: 22815755, PMCID: PMC3399858, DOI: 10.1371/journal.pone.0040514.
• Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.Li JZ, Paredes R, Ribaudo HJ, Kozal MJ, Svarovskaia ES, Johnson JA, Geretti AM, Metzner KJ, Jakobsen MR, Hullsiek KH, Ostergaard L, Miller MD, Kuritzkes DR. Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. The Journal Of Infectious Diseases 2013, 207: 893-7 PubMed ID: 23264671, PMCID: PMC3571444, DOI: 10.1093/infdis/jis925.
• Association between risk behaviors and antiretroviral resistance in HIV-infected patients receiving opioid agonist treatment.Tetrault JM, Kozal MJ, Chiarella J, Sullivan LE, Dinh AT, Fiellin DA. Association between risk behaviors and antiretroviral resistance in HIV-infected patients receiving opioid agonist treatment. Journal Of Addiction Medicine 2013, 7: 102-7 PubMed ID: 23388678, PMCID: PMC3618545, DOI: 10.1097/ADM.0b013e31827f9bdf.
• A study of financial incentives to reduce plasma HIV RNA among patients in care.Farber S, Tate J, Frank C, Ardito D, Kozal M, Justice AC, Scott Braithwaite R. A study of financial incentives to reduce plasma HIV RNA among patients in care. AIDS And Behavior 2013, 17: 2293-300 PubMed ID: 23404097, PMCID: PMC3742414, DOI: 10.1007/s10461-013-0416-1.
• Low-frequency NNRTI-resistant HIV-1 variants and relationship to mutational load in antiretroviral-naïve subjects.Gupta S, Lataillade M, Kyriakides TC, Chiarella J, St John EP, Webb S, Moreno EA, Simen BB, Kozal MJ. Low-frequency NNRTI-resistant HIV-1 variants and relationship to mutational load in antiretroviral-naïve subjects. Viruses 2014, 6: 3428-37 PubMed ID: 25256391, PMCID: PMC4189030, DOI: 10.3390/v6093428.
• Deep sequencing of HIV: clinical and research applications.Chabria SB, Gupta S, Kozal MJ. Deep sequencing of HIV: clinical and research applications. Annual Review Of Genomics And Human Genetics 2014, 15: 295-325 PubMed ID: 24821496, DOI: 10.1146/annurev-genom-091212-153406.
• Prevalence of WHO transmitted drug resistance mutations by deep sequencing in antiretroviral-naïve subjects in Hunan Province, China.Xiaobai Z, Xi C, Tian H, Williams AB, Wang H, He J, Zhen J, Chiarella J, Blake LA, Turenchalk G, Kozal MJ. Prevalence of WHO transmitted drug resistance mutations by deep sequencing in antiretroviral-naïve subjects in Hunan Province, China. PloS One 2014, 9: e98740 PubMed ID: 24896087, PMCID: PMC4045886, DOI: 10.1371/journal.pone.0098740.
• The VACS index accurately predicts mortality and treatment response among multi-drug resistant HIV infected patients participating in the options in management with antiretrovirals (OPTIMA) study.Brown ST, Tate JP, Kyriakides TC, Kirkwood KA, Holodniy M, Goulet JL, Angus BJ, Cameron DW, Justice AC. The VACS index accurately predicts mortality and treatment response among multi-drug resistant HIV infected patients participating in the options in management with antiretrovirals (OPTIMA) study. PloS One 2014, 9: e92606 PubMed ID: 24667813, PMCID: PMC3965438, DOI: 10.1371/journal.pone.0092606.
• Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.Baxter JD, Dunn D, White E, Sharma S, Geretti AM, Kozal MJ, Johnson MA, Jacoby S, Llibre JM, Lundgren J. Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Medicine 2015, 16 Suppl 1: 77-87 PubMed ID: 25711326, PMCID: PMC4341921, DOI: 10.1111/hiv.12236.
• Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers.Walker WE, Kurscheid S, Joshi S, Lopez CA, Goh G, Choi M, Barakat L, Francis J, Fisher A, Kozal M, Zapata H, Shaw A, Lifton R, Sutton RE, Fikrig E. Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers. Journal Of Virology 2015, 89: 5502-14 PubMed ID: 25740989, PMCID: PMC4442529, DOI: 10.1128/JVI.00118-15.
• Transmission of HIV drug resistance: lessons from sensitive screening assays.Geretti AM, Paredes R, Kozal MJ. Transmission of HIV drug resistance: lessons from sensitive screening assays. Current Opinion In Infectious Diseases 2015, 28: 23-30 PubMed ID: 25501541, DOI: 10.1097/QCO.0000000000000136.
• Deep sequencing of HIV-1 variants from paired plasma and cerebrospinal fluid during primary HIV infection.Gega A, Kozal MJ, Chiarella J, Lee E, Peterson J, Hecht FM, Liegler T, St John EP, Simen BB, Price RW, Spudich SS. Deep sequencing of HIV-1 variants from paired plasma and cerebrospinal fluid during primary HIV infection. Journal Of Virus Eradication 2015, 1: 264-268 PubMed ID: 26855971, PMCID: PMC4743659.
• DHHS/NIH Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Panel Member/Author. Released January 28, 2016.https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/1/panel-roster
• HIV Drug Resistance Mutations (DRMs) Detected by Deep Sequencing in Virologic Failure Subjects on Therapy from Hunan Province, China.Chen X, Zou X, He J, Zheng J, Chiarella J, Kozal MJ. HIV Drug Resistance Mutations (DRMs) Detected by Deep Sequencing in Virologic Failure Subjects on Therapy from Hunan Province, China. PloS One 2016, 11: e0149215 PubMed ID: 26895182, PMCID: PMC4760947, DOI: 10.1371/journal.pone.0149215.
• Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based Study.Helou E, Shenoi S, Kyriakides T, Landry ML, Kozal M, Barakat LA. Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based Study. Journal Of The International Association Of Providers Of AIDS Care 2017, 16: 261-266 PubMed ID: 27903948, PMCID: PMC5423832, DOI: 10.1177/2325957416680028.
• Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders.Fuchs M, Monto A, Bräu N, Charafeddine M, Schmidt W, Kozal M, Naggie S, Cheung R, Schnell G, Yu Y, Richards K, Mullally V, Cohen DE, Toro D. Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders. Journal Of Medical Virology 2019 PubMed ID: 31829433, PMCID: PMC7687116, DOI: 10.1002/jmv.25655.
• Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina JM, Grinsztejn B, Diaz R, Castagna A, Kumar P, Latiff G, DeJesus E, Gummel M, Gartland M, Pierce A, Ackerman P, Llamoso C, Lataillade M. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. The New England Journal Of Medicine 2020, 382: 1232-1243 PubMed ID: 32212519, DOI: 10.1056/NEJMoa1902493.
• SARS-CoV-2 detection in setting of viral swabs scarcity: Are MRSA swabs and viral swabs equivalent?Federman DG, Gupta S, Stack G, Campbell SM, Peaper DR, Dembry LM, Fisher A, Tarabar AF, Kozal M, Ruser CB. SARS-CoV-2 detection in setting of viral swabs scarcity: Are MRSA swabs and viral swabs equivalent? PloS One 2020, 15: e0237127 PubMed ID: 32756602, PMCID: PMC7406068, DOI: 10.1371/journal.pone.0237127.
• Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.Lataillade M, Lalezari JP, Kozal M, Aberg JA, Pialoux G, Cahn P, Thompson M, Molina JM, Moreno S, Grinsztejn B, Diaz RS, Castagna A, Kumar PN, Latiff GH, De Jesus E, Wang M, Chabria S, Gartland M, Pierce A, Ackerman P, Llamoso C. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. The Lancet. HIV 2020, 7: e740-e751 PubMed ID: 33128903, DOI: 10.1016/S2352-3018(20)30240-X.
• Fostemsavir for the treatment of HIV.Seval N, Frank C, Kozal M. Fostemsavir for the treatment of HIV. Expert Review Of Anti-infective Therapy 2021, 19: 961-966 PubMed ID: 33331202, DOI: 10.1080/14787210.2021.1865801.
• Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1.Ackerman P, Thompson M, Molina JM, Aberg J, Cassetti I, Kozal M, Castagna A, Martins M, Ramgopal M, Sprinz E, Treviño-Pérez S, Streinu-Cercel A, Latiff GH, Pialoux G, Kumar PN, Wang M, Chabria S, Pierce A, Llamoso C, Lataillade M. Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. AIDS (London, England) 2021, 35: 1061-1072 PubMed ID: 33946085, PMCID: PMC8183480, DOI: 10.1097/QAD.0000000000002851.
• Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals.Moldt B, Günthard HF, Workowski KA, Little SJ, Eron JJ, Overton ET, Lehmann C, Rokx C, Kozal MJ, Gandhi RT, Braun DL, Parvangada A, Li J, Martin R, Selzer L, Cox S, Margot N, Liu H, Slamowitz D, Makadzange T, Collins SE, Geleziunas R, Callebaut C. Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals. AIDS (London, England) 2022, 36: 205-214 PubMed ID: 34586088, DOI: 10.1097/QAD.0000000000003088.
• Fostemsavir: a first-in-class HIV-1 attachment inhibitor.Grant PM, Kozal MJ. Fostemsavir: a first-in-class HIV-1 attachment inhibitor. Current Opinion In HIV And AIDS 2022, 17: 32-35 PubMed ID: 34871189, DOI: 10.1097/COH.0000000000000712.